Recent studies using genetically engineered pig models have revealed that TP53 mutations drive a tumor spectrum, with circTP53 playing a crucial role in tumorigenesis.[41] This duality presents compelling evidence for considering circTP53 as a potential therapeutic target, particularly within the framework of personalized medicine that is tailored to p53 status. Here, TP53 is linked to neoplasm.